Williams, Kate http://orcid.org/0000-0003-4874-0334
Tickler, Georgina
Valdivielso, Pedro
Alonso, Jordi
Vera-Llonch, Montserrat
Cubells, Laia
Acaster, Sarah
Funding for this research was provided by:
Ionis Pharmaceuticals
Article History
Received: 14 March 2023
Accepted: 24 September 2023
First Online: 11 October 2023
Declarations
:
: The UK study was reviewed and approved by the WIRB-Copernicus Group Independent Review Board (IRB tracking number: #20200269). In Spain, the study was reviewed and approved on 24th September 2020 he Comité de Ética de la Investigación Provincial de Málaga. Verbal informed consent was taken and recorded at the start of each interview. Participants in Spain also returned a signed consent form to their clinician.
: Participants provided consent for their data to be published in peer-reviewed academic journals before taking part in the study.
: Kate Williams, Georgina Tickler, and Sarah Acaster are employees of Acaster Lloyd Consulting Ltd. Montserrat Vera-Llonch is an employee of Ionis Pharmaceuticals Inc. Laia Cubells was an employee of Akcea Therapeutics Inc. at the time of the research study being conducted. Pedro Valdivielso reports that he received honoraria as a speaker from Sanofi, Amgen, Amarin, Akcea, Daiichi-Sankyo, Servier, as advisor from Sanofi, Amgen, Amarin, Akcea, Daiichi-Sankyo, a grant from Ferrer, Sanofi and Sobi and support to travel from Daiichi-Sankyo, Servier, Sanofi, Amgen, Sobi, PTC. Jordi Alonso’s institution received consultancy fees from Ionis Pharmaceuticals Inc.